HBM invests EUR 20 million in Amicus28.04.2017 14:14
HBM Healthcare Investments announced the closing of a new equity investment of EUR 20 million in two tranches into the privately held and Switzerland based Amicus SA. The financing will allow Amicus to accelerate the growth of its pharmaceutical business in Central and Eastern Europe (CEE).
Amicus is a revenue generating company and specializes in the distribution of pharmaceutical products, medical equipment and over the counter brands in countries where the originators decide not to maintain a direct presence. Leading healthcare companies such as Alcon, Bristol Myers Squibb, Cardinal Health, Expanscience, Grupo Ferrer, General Electric, Genexo, Pfizer, PharmaNutra and Salvat Biotech, amongst others, are represented by Amicus.
Amicus SA Switzerland was founded in late 2013 and is registered in Baar, Switzerland. The company registered 100%-owned affiliates in Bosnia & Herzegovina, Croatia, Estonia, Kosovo, Latvia, Lithuania, Macedonia, Montenegro, Serbia and Slovenia in the summer and fall of 2014. Amicus’ owners and senior management were the founding group and executive team of PharmaSwiss SA, which was sold in March, 2011 to Valeant International Inc. Prior to that, most of Amicus’ senior managers worked at Bristol-Myers Squibb affiliates in Central and Eastern Europe. HBM Healthcare Investments was a significant shareholder of PharmaSwiss SA from 2007 until 2011 when the company was sold.
“We are delighted to welcome HBM Healthcare Investments, a widely-respected pharma and biotech investor, as a keystone shareholder in Amicus", commented Petr Nemec, Founding Partner of Amicus S.A. "They bring to our company enhanced corporate governance, a wealth of new contacts, ideas and great energy. Further, with this significant cash injection, HBM is putting Amicus in pole position to accelerate its growth in Central and Eastern Europe and beyond. On a personal basis, I’d like to add that I am thrilled to re-establish the productive and friendly relationship that our management group enjoyed with HBM previously," continued Nemec. “Re-uniting with HBM marks a full turning of the circle, and I am simply delighted to work with the HBM team once again. They are a positive business force.”
"The HBM investment is yet another confirmation that Amicus S.A. is fast becoming the unavoidable alternative partner for those healthcare companies that choose not to undertake their own marketing and distribution in Central & Eastern European countries,” remarked Jean-Michel Lespinasse, CEO of Amicus SA " Through the biotech and pharmaceutical network of HBM, as well as via leveraging our newly-expanded financial resources, we will accelerate the growth of our portfolio, and further expand our geographical reach.”